Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report

Clin Pharmacol Ther. 2021 Feb;109(2):292-294. doi: 10.1002/cpt.1978. Epub 2020 Aug 2.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Drug Development / methods
  • Humans
  • Liver / drug effects*
  • Liver Cirrhosis / drug therapy*
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Pharmacology, Clinical / methods
  • Risk Factors